While acknowledging the complexity of drug-gene interactions, these findings, when superimposed on the results reported here, invite speculation that β-blocker therapy, with or without recently developed cardiac myosin activation therapies (28), may be useful for treating HLHS subjects who carry pathogenic MYH6 variants. Here, MYH6 is linked to hypoplastic left heart syndrome.